CD163 and neoplasm: The risk of death was found to decrease slightly but in a statistically significant manner as the number of CD14+ (sHR: 0.997, 95% CI [0.993-1], p = 0.04), CD68+ (sHR: 0.995, 95% CI [0.991-1], p = 0.05) and CD163+(sHR: 0.995, 95% CI [0.999-1], p = 0.02) myeloid cells in the intratumoral tumor (IT Tumor) compartment.